Search - tctmd.com

Displaying 501 - 520 of 963

Sort: Relevancy | Date

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

News Conference News ACC 2020

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

April 01, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

E-Cigarettes Added to Counseling Can Help Smokers Quit at 12 Weeks

News Conference News ACC 2020

E-Cigarettes Added to Counseling Can Help Smokers Quit at 12 Weeks

March 31, 2020

PCI Equal to Surgery in Left Main CAD: PRECOMBAT at 10 Years

News Conference News ACC 2020

PCI Equal to Surgery in Left Main CAD: PRECOMBAT at 10 Years

Michael O'Riordan

March 30, 2020

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

News Conference News ACC 2020

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

March 30, 2020

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

News Conference News ACC 2020

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

Yael L. Maxwell

March 30, 2020

A-fib Patients Undergoing TAVR Do Better With OAC Alone: POPular TAVI

News Conference News ACC 2020

A-fib Patients Undergoing TAVR Do Better With OAC Alone: POPular TAVI

March 29, 2020

Anatomic Burden, Ischemia Severity, and Outcomes in ISCHEMIA

News Conference News ACC 2020

Anatomic Burden, Ischemia Severity, and Outcomes in ISCHEMIA

March 29, 2020

Genotype-Based P2Y12 Prescribing Post-PCI Falls Short in TAILOR-PCI

News Conference News ACC 2020

Genotype-Based P2Y12 Prescribing Post-PCI Falls Short in TAILOR-PCI

Yael L. Maxwell

March 28, 2020

A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA

News Conference News ACC 2020

A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA

Michael O'Riordan

March 28, 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

News Conference News ACC 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

March 28, 2020

Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds

News Conference News ACC 2020

Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds

March 25, 2020

Statins May Have Protective Effect on Chemotherapy-Induced Cardiotoxicity

News Conference News ACC 2020

Statins May Have Protective Effect on Chemotherapy-Induced Cardiotoxicity

Yael L. Maxwell

March 19, 2020

Industry Payments to Vascular Neurologists Jump in the Thrombectomy Era

News Conference News ISC 2020

Industry Payments to Vascular Neurologists Jump in the Thrombectomy Era

February 29, 2020

Optimal Time to Start Anticoagulation After Stroke Remains Unclear

News Conference News ISC 2020

Optimal Time to Start Anticoagulation After Stroke Remains Unclear

February 27, 2020

Telehealth Program Helps Minority Stroke Survivors Control BP

News Conference News ISC 2020

Telehealth Program Helps Minority Stroke Survivors Control BP

February 26, 2020

PCI-Related MIs Not Linked to Mortality at 1 Year: Onyx ONE

News Conference News CRT 2020

PCI-Related MIs Not Linked to Mortality at 1 Year: Onyx ONE

Michael O'Riordan

February 25, 2020

SKIP Questions Need for IV Thrombolysis Before Stroke Thrombectomy

News Conference News ISC 2020

SKIP Questions Need for IV Thrombolysis Before Stroke Thrombectomy

February 25, 2020

Another Neuroprotective Agent Fails in Acute Stroke . . . Or Does It?

News Conference News ISC 2020

Another Neuroprotective Agent Fails in Acute Stroke . . . Or Does It?

February 21, 2020

Antihypertensive Treatment is Subpar After ICH

News Conference News ISC 2020

Antihypertensive Treatment is Subpar After ICH

February 19, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.